From: Multiple Sclerosis News Today
By:
Ocrevus (ocrelizumab) continues to be the most commonly prescribed therapy for progressive forms of multiple sclerosis (MS), including primary progressive MS (PPMS) and secondary progressive MS (SPMS), according to an analysis from the market intelligence firm Spherix Global Insights.
However, other therapies are “gaining traction” among SPMS patients, the report finds…(read more)
